BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 3:13:00 PM | Browse: 1339 | Download: 1500
 |
Received |
|
2013-03-29 09:58 |
 |
Peer-Review Started |
|
2013-03-29 13:48 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-04-18 19:41 |
 |
Revised |
|
2013-05-11 20:25 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-06-18 10:59 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-06-19 00:41 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-08-06 11:35 |
 |
Publish the Manuscript Online |
|
2013-08-15 11:51 |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Autobiography |
| Article Title |
Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Plamen Kozlovski, James Foley, Qing Shao, Valentina Lukashevich and Wolfgang Kothny |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Novartis Pharma AG |
|
|
| Corresponding Author |
Plamen Kozlovski, MD, Novartis Pharma AG, CH-4002 Basel, Switzerland. plamen.kozlovski@novartis.com |
| Key Words |
Asian; DPP-4 inhibitor; Hypoglycemia; Insulin; Oral antidiabetic drug; Type 2 diabetes; Vildagliptin |
| Core Tip |
In Asian patients, vildagliptin added to stable dose of insulin, with or without concomitant metformin, significantly improves glycemic control without increase in weight and hypoglycemia incidence. |
| Publish Date |
2013-08-15 11:51 |
| Citation |
Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 2013; 4(4): 151-156 |
| URL |
http://www.wjgnet.com/1948-9358/full/v4/i4/151.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v4.i4.151 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.